Dirk Kosemund
Bayer (Germany)(DE)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Microtubule and mitosis dynamics, Protein Degradation and Inhibitors, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer(2017)178 cited
- → Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity(2016)117 cited
- → Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer(2021)69 cited
- → Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase(2020)53 cited
- → Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops(2017)28 cited
- → Abstract 2828: Rapid identification of potent and highly selective, oral PTEFb Inhibitor BAY 1143572 with first in class potential(2015)7 cited
- → Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity(2015)2 cited
- → CCDC 1569510: Experimental Crystal Structure Determination(2017)
- → CCDC 2005811: Experimental Crystal Structure Determination(2021)